Tarsus Pharmaceuticals to Present 11 Abstracts at AAOpt 2026 Meeting
News related to:Tarsus Pharmaceuticals, Inc · 3 min read
IRVINE, Calif., Sept. 29, 2026 /CourierPR/ -- Tarsus Pharmaceuticals, Inc. is set to present 11 scientific abstracts at the American Academy of Optometry (AAOpt) 2026 Annual Meeting, which will take place from September 30 to October 3 in Anaheim, California. The company's focus on Demodex blepharitis, ocular rosacea, and the real-world impact of its XDEMVY® (lotilaner ophthalmic solution) 0.25% will be highlighted through these presentations.
Among the abstracts, one will delve into the real-world longitudinal study of patients with Demodex blepharitis and soft contact lens wear in the United States. The interim data analysis will be presented on October 1, 2026, from 4:30 to 6:30 PM Pacific Daylight Time, in the Anaheim Convention Center (ACC), Exhibit Hall. Keith Wan, O.D., will serve as the presenter.
Another abstract will explore the efficacy of lotilaner 0.25% and tea tree oil in treating Demodex blepharitis, with a systematic review and meta-analysis. This will also be presented on October 1, 2026, from 4:30 to 6:30 PM, in the ACC, Exhibit Hall, with Ian B. Gaddie, O.D., as the presenter.
A retrospective chart review of Demodex blepharitis prevalence among patients with chalazia and/or hordeola will be discussed. This will be presented on the same day, October 1, 2026, from 4:30 to 6:30 PM, in the ACC, Exhibit Hall, by Andrew McLeod, O.D.
The prevalence of ocular rosacea in U.S. eye care settings will be examined through a multicenter retrospective chart review. This abstract will be presented on October 1, 2026, from 4:30 to 6:30 PM, in the ACC, Exhibit Hall, with Mile Brujic, O.D., as the presenter.
An assessment of dry eye questionnaires for Demodex blepharitis, based on a targeted literature review, will also be presented on October 1, 2026, from 4:30 to 6:30 PM, in the ACC, Exhibit Hall, by Walt Whitley, O.D.
A 9-month follow-up study of patients with Demodex blepharitis in the United States will be discussed on October 1, 2026, from 4:30 to 6:30 PM, in the ACC, Exhibit Hall, with Vanesa Flores, O.D., as the presenter.
The real-world clinician re-treatment practices and decision drivers with XDEMVY for Demodex blepharitis will be presented on October 1, 2026, from 4:30 to 6:30 PM, in the ACC, Exhibit Hall, by Cecelia Koetting, O.D.
Patient-reported satisfaction and factors associated with perceived benefit of XDEMVY for Demodex blepharitis will be discussed on October 1, 2026, from 4:30 to 6:30 PM, in the ACC, Exhibit Hall, with Jessilin Quint, O.D., as the presenter.
A systematic review of associations between Demodex infestation and meibomian gland structure and function will be presented on October 1, 2026, from 4:30 to 6:30 PM, in the ACC, Exhibit Hall, by Bridgitte Shen Lee, O.D.
Lastly, a systematic review of ocular bacterial and fungal co-infestation in Demodex infestation will be discussed on October 2, 2026, from 4:00 to 4:15 PM, in ACC, Room 255 C, with Selina McGee, O.D., as the presenter.
Demodex blepharitis, a common lid margin disease, affects as many as 25 million Americans, based on the Titan study, which indicated that 58% of patients presenting to U.S. eye care clinics have collarettes, a pathognomonic sign of Demodex mite infestation. Additionally, at least 45 million people annually visit an eye care clinic.
XDEMVY (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, is a novel prescription eye drop designed to treat Demodex blepharitis by targeting and eradicating the root cause of the disease, Demodex mite infestation. The drug was evaluated in two pivotal trials involving over 800 patients with twice-daily dosing for six weeks. Both trials met their primary and secondary endpoints, with statistical significance and no serious treatment-related adverse events. Most patients found the XDEMVY eye drop to be neutral to very comfortable. The most common ocular adverse reactions observed in the studies were instillation site stinging and burning, reported in 10% of patients. Other ocular adverse reactions reported by less than 2% of patients were chalazion/hordeolum and punctate keratitis.
Tarsus Pharmaceuticals, Inc. is also developing TP-04 for the potential treatment of ocular rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease, both of which are in Phase 2.